THE Ministry of Health Malaysia (MOH) has assured that the supply of medicines in the country remains stable and under control, despite the conflict in the Middle East, which has raised concerns about the global supply chain.
In a statement, the MOH said that, based on the current assessment, the impact of the conflict on the supply of medicines in Malaysia in the short term is minimal.
“The supply of medicines in the country is stable and under control. Based on the current assessment, the impact of the conflict in the Middle East in the short term is minimal,” the statement read today.
According to the MOH, the stock levels of medicines at health facilities under the ministry are kept between one and three months according to current consumption needs.
In addition, the supply is also supported by buffer stocks of up to two months at the concessionaire level for medicines supplied through logistics concessions.
Meanwhile, the MOH announced that monitoring of the supply of medicines is carried out continuously through existing mechanisms, including the supply disruption reporting system by the Product Registration Holder (PRH) operated by the National Pharmaceutical Regulatory Division (NPRA).
As of March 22, 2026, the Ministry of Health announced that there was no increase in the trend in PRH reporting involving drug supply disruptions.
Feedback from the local pharmaceutical industry showed that manufacturers had stocks of raw materials for up to three months and finished products for around two months.
At the same time, importers were also closely monitoring their respective supply chains to ensure that supplies remained adequate.
The MOH also announced that it would continue to closely monitor the development of the conflict in the Middle East and was committed to taking proactive measures to ensure the security of drug supply in the country.
“The MOH will continue to closely monitor the development of the conflict in the Middle East and is committed to taking proactive measures, including the establishment of a task force consisting of the pharmaceutical industry and relevant stakeholders to monitor and ensure the security of drug supply, especially involving drugs under the National Essential Medicines List (NEML) in Malaysia,” the statement added. – March 23, 2026
